Upregulation of complement inhibitors in association with vulnerable cells following contusion-induced spinal cord injury

Journal of Neurotrauma

Volumn 22, Issue 3, 2005, Pages 382-397

  Anderson, Aileen J ^a   Najbauer, Joseph ^a   Huang, Wencheng ^b   Young, Wise ^b   Robert, Stephanie ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

Complement cascade; Demyelination; Immune response; Inflammation; Neurodegeneration; Neuron; Oligodendrocyte

Indexed keywords

CLUSTERIN; COMPLEMENT FACTOR H; COMPLEMENT INHIBITOR; REGULATOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LABELING; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT CLASSICAL PATHWAY; CONTROLLED STUDY; CONTUSION; DEMYELINATION; DISEASE SEVERITY; IMMUNE RESPONSE; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; INFLAMMATION; LAMINECTOMY; NERVE CELL; NERVE DEGENERATION; NONHUMAN; OLIGODENDROGLIA; PROTEIN EXPRESSION; PROTEIN INDUCTION; RAT; RAT STRAIN; SPINAL CORD INJURY; TECHNIQUE; UPREGULATION;

ANIMALS; COMPLEMENT INACTIVATOR PROTEINS; NEUROGLIA; NEURONS; RATS; RATS, LONG-EVANS; SPINAL CORD INJURIES; THORACIC VERTEBRAE; UP-REGULATION;

EID: 15944363121     PISSN: 08977151     EISSN: None     Source Type: Journal    
DOI: 10.1089/neu.2005.22.382     Document Type: Article

References (94)

1. ANDERSON, A.J., ROBERT, S., HUANG, W., YOUNG, W., and COTMAN, C.W. (2004). Activation of complement pathways after contusion-induced spinal cord injury. J. Neurotrauma 21, 1831-1846.
2. ANDERSON, A.J., SU, J.H., and COTMAN, C.W. (1996). DNA damage and apoptosis in Alzheimer's disease: colocalization with c-Jun immunoreactivity, relationship to brain area, and effect of postmortem delay. J. Neurosci. 16, 1710-1719.
3. AULT, B.H., SCHMIDT, B.Z., FOWLER, N.L., et al. (1997). Human factor H deficiency. Mutations in framework cysteine residues and block in H protein secretion and intracellular catabolism. J. Biol. Chem. 272, 25168-25175.
4. BARNUM, S.R. (1999). Inhibition of complement as a therapeutic approach in inflammatory central nervous system (CNS) disease. Mol. Med. 5, 569-582.
5. BARTL, M.M., LUCKENBACH, T., BERGNER, O., ULLRICH, O., and KOCH-BRANDT, C. (2001). Multiple receptors mediate apoJ-dependent clearance of cellular debris into nonprofessional phagocytes. Exp. Cell Res. 271, 130-141.
6. BELLANDER, B.M., VON HOLST, H., FREDMAN, P., and SVENSSON, M. (1996). Activation of the complement cascade and increase of clusterin in the brain following a cortical contusion in the adult rat. J. Neurosurg. 85, 468-475.
7. BLASCHUK, O., BURDZY, K., and FRITZ, I.B. (1983). Purification and characterization of a cell-aggregating factor (clusterin), the major glycoprotein in ram rete testis fluid. J. Biol. Chem. 258, 7714-7720.
8. 2+. J. Immunol. 137, 263-270.
9. CARNEY, D.F., KOSKI, C.L., and SHIN, M.L. (1985). Elimination of terminal complement intermediates from the plasma membrane of nucleated cells: the rate of disappearance differs for cells carrying C5b-7 or C5b-8 or a mixture of C5b-8 with a limited number of C5b-9. J. Immunol. 134, 1804-1809.
10. CONSTANTINI, S., and YOUNG, W. (1994). The effects of methylprednisolone and the ganglioside GM1 on acute spinal cord injury in rats. J. Neurosurg. 80, 97-111.
11. DAILEY, A.T., AVELLINO, A.M., BENTHEM, L., SILVER, J., and KLIOT, M. (1998) Complement depletion reduces macrophage infiltration and activation during Wallerian degeneration and axonal regeneration. J. Neurosci. 18, 6713-6722.
12. DASHIELL, S.M., and KOSKI, C.L. (1999). Sublytic terminal complement complexes decrease Po Gene expression in Schwann cells. J. Neurochem. 73, 2321-2330.
13. DASHIELL, S.M., RUS, H., and KOSKI, C.L. (2000). Terminal complement complexes concomitantly stimulate proliferation and rescue of Schwann cells from apoptosis. Glia 30, 187-198.
14. DAVOUST, N., NATAF, S., REIMAN, R., HOLERS, M.V., CAMPBELL, I.L., and BARNUM, S.R. (1999). Central nervous system-targeted expression of the complement inhibitor sCrry prevents experimental allergic encephalomyelitis. J. Immunol. 163, 6551-6556.
15. DISCIPIO, R.G., DAFFERN, P.J., JAGELS, M.A., BROIDE, D.H., and SRIRAMARAO, P. (1999). A comparison of C3a and C5a-mediated stable adhesion of rolling eosinophils in postcapillary venules and transendothelial migration in vitro and in vivo. J. Immunol. 162, 1127-1136.
16. DOYLE, H.A., and MAMULA, M.J. (2001). Post-translational protein modifications in antigen recognition and autoimmunity. Trends Immunol. 22, 443-449.
17. DOYLE, H.A., and MAMULA, M.J. (2002). Posttranslational protein modifications: new flavors in the menu of autoantigens. Curr. Opin. Rheumatol. 14, 244-249.
18. DUSART, I., and SCHWAB, M.E. (1994). Secondary cell death and the inflammatory reaction after dorsal hemisection of the rat spinal cord. Eur. J. Neurosci. 6, 712-724.
19. DYER, J.K., BOURQUE, J.A., and STEEVES, J.D. (1998). Regeneration of brainstem-spinal axons after lesion and immunological disruption of myelin in adult rat. Exp. Neurol. 154, 12-22.
20. EGGLETON, P., REID, K.B., and TENNER, A.J. (1998). C1q-how many functions? How many receptors? Trends Cell Biol. 8, 428-431.
21. EIKELENBOOM, P., and VEERHUIS, R. (1996). The role of complement and activated microglia in the pathogenesis of Alzheimer's disease. Neurobiol. Aging 17, 673-680.
22. FEARON, D.T., and WONG, W.W. (1983). Complement ligand-receptor interactions that mediate biological responses. Annu. Rev. Immunol. 1, 243-271.
23. GASQUE, P., DEAN, Y.D., MCGREAL, E.P., VANBEEK, J., and MORGAN, B.P. (2000). Complement components of the innate immune system in health and disease in the CNS. Immunopharmacology 49, 171-186.
24. GASQUE, P., FONTAINE, M., and MORGAN, B.P. (1995). Complement expression in human brain. Biosynthesis of terminal pathway components and regulators in human glial cells and cell lines. J. Immunol. 154, 4726-4733.
25. GASQUE, P., THOMAS, A., FONTAINE, M., and MORGAN, B.P. (1996). Complement activation on human neuroblastoma cell lines in vitro: route of activation and expression of functional complement regulatory proteins. J. Neuroimmunol. 66, 29-40.
26. GEWURZ, H., YING, S.C., JIANG, H., and LINT, T.F. (1993). Nonimmune activation of the classical complement pathway. Behring Inst. Mitt. 93, 138-147.
27. GOLDSBY, R.A., KINDT, T.J., and OSBORNE, B.A. (2000). Kuby Immunology, 4th ed. W.H. Freeman: New York.
28. GREWAL, R.P., MORGAN, T.E., and FINCH, C.E. (1999). C1qB and clusterin mRNA increase in association with neurodegeneration in sporadic amyotrophic lateral sclerosis. Neurosci. Lett. 271, 65-67.
29. GUTHRIE, K.M., ANDERSON, A.J., LEON, M., and GALL, C.M. (1993). Odor-induced increases in c-fos mRNA reveal an anatomical "unit" for odor processing in olfactory bulb. Proc. Natl. Acad. Sci. USA 90, 3329-3333.
30. HAN, B.H., DEMATTOS, R.B., DUGAN, L.L., et al. (2001). Clusterin contributes to caspase-3-independent brain injury following neonatal hypoxia-ischemia. Nat. Med. 7, 338-343.
31. HANSCH, G.M. (1992). The complement attack phase: control of lysis and non-lethal effects of C5b-9. Immunopharmacology 24, 107-117.
32. HAUBEN, E., and SCHWARTZ, M. (2003). Therapeutic vaccination for spinal cord injury: helping the body to cure itself. Trends Pharmacol. Sci. 24, 7-12.
33. HUANG, J., KIM, L.J., MEALEY, R., et al. (1999). Neuronal protection in stroke by an sLex-glycosylated complement inhibitory protein. Science 285, 595-599.
34. HUMPHREYS, D., HOCHGREBE, T.T., EASTERBROOK-SMITH, S.B., TENNISWOOD, M.P., and WILSON, M.R. (1997). Effects of clusterin overexpression on TNFalpha- and TGFbeta-mediated death of L929 cells. Biochemistry 36, 15233-15243.
35. IIDA, K., WHITLOW, M.B., and NUSSENZWEIG, V. (1991). Membrane vesiculation protects erythrocytes from destruction by complement. J. Immunol. 147, 2638-2642.
36. ITAGAKI, S., AKIYAMA, H., SAITO, H., and McGEER, P.L. (1994). Ultrastructural localization of complement membrane attack complex (MAC)-like immunoreactivity in brains of patients with Alzheimer's disease. Brain Res. 645, 78-84.
37. JOHNSON, S., YOUNG-CHAN, C.S., LAPING, N.J., and FINCH, C.E. (1996). Perforant path transection induces complement C9 deposition in hippocampus. Exp. Neurol. 138, 198-205.
38. JONES, S.E., and JOMARY, C. (2002). Clusterin. Int. J. Biochem. Cell Biol. 34, 427-431.
39. JONES, T.B., BASSO, D.M., SODHI, A., et al. (2002). Pathological CNS autoimmune disease triggered by traumatic spinal cord injury: implications for autoimmune vaccine therapy. J. Neurosci. 22, 2690-2700.
40. JUNG, S., TOYKA, K.V., and HARTUNG, H.P. (1995). Soluble complement receptor type 1 inhibits experimental autoimmune neuritis in Lewis rats. Neurosci. Lett. 200, 167-170.
41. KEIRSTEAD, H.S., HUGHES, H.C., and BLAKEMORE, W.F. (1998). A quantifiable model of axonal regeneration in the demyelinated adult rat spinal cord. Exp. Neurol. 151, 303-313.
42. KISSINGER, C., SKINNER, M.K., and GRISWOLD, M.D. (1982). Analysis of Sertoli cell-secreted proteins by two-dimensional gel electrophoresis. Biol. Reprod. 27, 233-240.
43. KLIMASCHEWSKI, L., OBERMULLER, N., and WITZGALL, R. (2001). Regulation of clusterin expression following spinal cord injury. Cell Tissue Res. 306, 209-216.
44. LAKINS, J.N., POON, S., EASTERBROOK-SMITH, S.B., CARVER, J.A., TENNISWOOD, M.P., and WILSON, M.R. (2002). Evidence that clusterin has discrete chaperone and ligand binding sites. Biochemistry 41, 282-291.
45. LESKOV, K.S., KLOKOV, D.Y., LI, J., KINSELLA, T.J., and BOOTHMAN, D.A. (2003). Synthesis and functional analyses of nuclear clusterin: a cell death protein. J. Biol. Chem. 278, 11590-11600.
46. LINDAHL, G., SJOBRING, U., and JOHNSSON, E. (2000). Human complement regulators: a major target for pathogenic microorganisms. Curr. Opin. Immunol. 12, 44-51.
47. LIU, L., PERSSON, J.K., SVENSSON, M., and ALDSKOGIUS, H. (1998). Glial cell responses, complement, and clusterin in the central nervous system following dorsal root transection. Glia 23, 221-238.
48. LIU, L., SVENSSON, M., and ALDSKOGIUS, H. (1999). Clusterin upregulation following rubrospinal tract lesion in the adult rat. Exp. Neurol. 157, 69-76.
49. LIU, L., TORNQVIST, E., MATTSSON, P., et al. (1995). Complement and clusterin in the spinal cord dorsal horn and gracile nucleus following sciatic nerve injury in the adult rat. Neuroscience 68, 167-179.
50. MAKRIDES, S.C. (1998). Therapeutic inhibition of the complement system. Pharmacol. Rev. 50, 59-87.
51. MAY, P.C., and FINCH, C.E. (1992). Sulfated glycoprotein 2: new relationships of this multifunctional protein to neurodegeneration. Trends Neurosci. 15, 391-396.
52. MCLAUGHLIN, L., ZHU, G., MISTRY, M., et al. (2000). Apolipoprotein J/clusterin limits the severity of murine autoimmune myocarditis. J. Clin. Invest. 106, 1105-1113.
53. MEDZHITOV, R., and JANEWAY, C.A., JR. (2002). Decoding the patterns of self and nonself by the innate immune system. Science 296, 298-300.
54. MICHEL, D., CHATELAIN, G., NORTH, S., and BRUN, G. (1997). Stress-induced transcription of the clusterin/apoJ gene. Biochem. J. 328, 45-50.
55. MICHEL, D., MOYSE, E., TREMBLEAU, A., JOURDAN, F., and BRUN, G. (1997). Clusterin/ApoJ expression is associated with neuronal apoptosis in the olfactory mucosa of the adult mouse. J. Cell Sci. 110, 1635-1645.
56. MORGAN, B.P. (1989). Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects. Biochem. J. 264, 1-14.
57. MORGAN, B.P. (1995). Physiology and pathophysiology of complement: progress and trends. Crit. Rev. Clin. Lab. Sci. 32, 265-298.
58. MORGAN, B.P., DANKERT, J.R., and ESSER, A.F. (1987). Recovery of human neutrophils from complement attack: removal of the membrane attack complex by endocytosis and exocytosis. J. Immunol. 138, 246-253.
59. MURPHY, B.F., KIRSZBAUM, L., WALKER, I.D., and D'APICE A.J. (1988). SP-40,40, a newly identified normal human serum protein found in the SC5b-9 complex of complement and in the immune deposits in glomerulonephritis. J. Clin. Invest. 81, 1858-1864.
60. NEWKIRK, M.M., APOSTOLAKOS, P., NEVILLE, C., and FORTIN, P.R. (1999). Systemic lupus erythematosus, a disease associated with low levels of clusterin/apoJ, an antiinflammatory protein. J. Rheumatol. 26, 597-603.
61. NOBLE, L.J., and WRATHALL, J.R. (1989). Distribution and time course of protein extravasation in the rat spinal cord after contusive injury. Brain Res. 482, 57-66.
62. OLBY, N.J., and BLAKEMORE, W.F. (1996). A new method of quantifying the extent of tissue loss following spinal cord injury in the rat. Exp. Neurol. 138, 82-92.
63. OLLERT, M.W., DAVID, K., BREDEHORST, R., and VOGEL, C.W. (1995). Classical complement pathway activation on nucleated cells. Role of factor H in the control of deposited C3b. J. Immunol. 155, 4955-4962.
64. PIDDLESDEN, S.J., JIANG, S., LEVIN, J.L., VINCENT, A., and MORGAN, B.P. (1996). Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis. J. Neuroimmunol. 71, 173-177.
65. PIDDLESDEN, S.J., STORCH, M.K., HIBBS, M., FREEMAN, A.M., LASSMANN, H., and MORGAN, B.P. (1994). Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis. J. Immunol. 152, 5477-5484.
66. POON, S., EASTERBROOK-SMITH, S.B., RYBCHYN, M.S., CARVER, J.A., and WILSON, M.R. (2000). Clusterin is an ATP-independent chaperone with very broad substrate specificity that stabilizes stressed proteins in a folding-competent state. Biochemistry 39, 15953-15960.
67. POON, S., TREWEEK, T.M., WILSON, M.R., EASTERBROOK-SMITH, S.B., and CARVER, J.A. (2002). Clusterin is an extracellular chaperone that specifically interacts with slowly aggregating proteins on their off-folding pathway. FEBS Lett. 513, 259-266.
68. POPOVICH, P.G., HORNER, P.J., MULLIN, B.B., and STOKES, B.T. (1996). A quantitative spatial analysis of the blood-spinal cord barrier. I. Permeability changes after experimental spinal contusion injury. Exp. Neurol. 142, 258-275.
69. POPOVICH, P.G., and JONES, T.B. (2003). Manipulating neuroinflammatory reactions in the injured spinal cord: back to basics. Trends Pharmacol. Sci. 24, 13-17.
70. POPOVICH, P.G., WEI, P., and STOKES, B.T. (1997). Cellular inflammatory response after spinal cord injury in Sprague-Dawley and Lewis rats. J. Comp. Neurol. 377, 443-464.
71. RABCHEVSKY, A.G., FUGACCIA, I., SULLIVAN, P.G., BLADES, D.A., and SCHEFF, S.W. (2002). Efficacy of methylprednisolone therapy for the injured rat spinal cord. J. Neurosci. Res. 68, 7-18.
72. ROSENBERG, M.E., GIRTON, R., FINKEL, D., et al. (2002). Apolipoprotein J/clusterin prevents a progressive glomerulopathy of aging. Mol. Cell Biol. 22, 1893-1902.
73. ROZOVSKY, I., MORGAN, T.E., WILLOUGHBY, D.A., et al. (1994). Selective expression of clusterin (SGP-2) and complement C1qB and C4 during responses to neurotoxins in vivo and in vitro. Neuroscience 62, 741-758.
74. RUS, H.G., NICULESCU, F., and SHIN, M.L. (1996). Sublytic complement attack induces cell cycle in oligodendrocytes. J. Immunol. 156, 4892-4900.
75. RUS, H.G., NICULESCU, F.I., and SHIN, M.L. (2001). Role of the C5b-9 complement complex in cell cycle and apoptosis. Immunol. Rev. 180, 49-55.
76. SHIRAZI, Y., RUS, H.G., MACKLIN, W.B., and SHIN, M.L. (1993). Enhanced degradation of messenger RNA encoding myelin proteins by terminal complement complexes in oligodendrocytes. J. Immunol. 150, 4581-4590.
77. SILKENSEN, J.R., HIRSCH, A.T., LUNZER, M.M., et al. (1998). Temporal induction of clusterin in the peri-infarct zone after experimental myocardial infarction in the rat. J. Lab. Clin. Med. 131, 28-35.
78. SILVERMAN, B.A., CARNEY, D.F., JOHNSTON, C.A., VANGURI, P., and SHIN, M.L. (1984). Isolation of membrane attack complex of complement from myelin membranes treated with serum complement. J. Neurochem. 42, 1024-1029.
79. SOANE, L., RUS, H., NICULESCU, F., and SHIN, M.L. (1999). Inhibition of oligodendrocyte apoptosis by sublytic C5b-9 is associated with enhanced synthesis of bcl-2 and mediated by inhibition of caspase-3 activation. J. Immunol. 163, 6132-6138.
80. SPETH, C., DIERICH, M.P., and GASQUE, P. (2002). Neuroinvasion by pathogens: a key role of the complement system. Mol. Immunol. 38, 669-679.
81. SPIEGEL, K., EMMERLING, M.R., and BARNUM, S.R. (1998). Strategies for inhibition of complement activation in the treatment of neurodegenerative diseases, in: Neuroinflammation: Mechanisms and Management. P.L. Wood (ed), Humana Press: Totowa, NJ, pps. 129-176.
82. SVENSSON, M., LIU, L., MATTSSON, P., MORGAN, B.P., and ALDSKOGIUS, H. (1995). Evidence for activation of the terminal pathway of complement and upregulation of sulfated glycoprotein (SGP)-2 in the hypoglossal nucleus following peripheral nerve injury. Mol. Chem. Neuropathol. 24, 53-68.
83. TAYLOR, C.M. (2001). Complement factor H and the haemolytic uraemic syndrome. Lancet 358, 1200-1202.
84. TENNER, A.J. (2001). Complement in Alzheimer's disease: opportunities for modulating protective and pathogenic events. Neurobiol. Aging 22, 849-861.
85. TORNQVIST, E., LIU, L., ALDSKOGIUS, H., HOLST, H.V., and SVENSSON, M. (1996). Complement and clusterin in the injured nervous system. Neurobiol. Aging 17, 695-705.
86. TROUGAKOS, I.P., and GONOS, E.S. (2002). Clusterin/ apolipoprotein J in human aging and cancer. Int. J. Biochem. Cell Biol. 34. 1430-1448.
87. VASTHARE, U.S., BARONE, F.C., SARAU, H.M., et al. (1998). Complement depletion improves neurological function in cerebral ischemia. Brain Res. Bull. 45, 413-419.
88. WEHRLI, P., CHARNAY, Y., VALLET, P., et al. (2001). Inhibition of post-ischemic brain injury by clusterin overexpression. Nat. Med. 7, 977-979.
89. WILSON, M.R., and EASTERBROOK-SMITH, S.B. (2000). Clusterin is a secreted mammalian chaperone. Trends Biochem. Sci. 25, 95-98.
90. YANG, C.R., LESKOV, K., HOSLEY-EBERLEIN, K., et al. (2000). Nuclear clusterin/XIP8, an x-ray-induced Ku70-binding protein that signals cell death. Proc. Natl. Acad. Sci. USA 97, 5907-5912.
91. YU, J.X., BRADT, B.M., and COOPER, N.R. (2002). Constitutive expression of proinflammatory complement components by subsets of neurons in the central nervous system. J. Neuroimmunol. 123, 91-101.
92. ZIPFEL, P.F. (2001). Hemolytic uremic syndrome: how do factor H mutants mediate endothelial damage? Trends Immunol. 22, 345-348.
93. ZIPFEL, P.F., HELLWAGE, J., FRIESE, M.A., HEGASY, G., JOKIRANTA, S.T., and MERI, S. (1999). Factor H and disease: a complement regulator affects vital body functions. Mol. Immunol. 36, 241-248.
94. ZIPFEL, P.F., JOKIRANTA, T.S., HELLWAGE, J., KOISTINEN, V., and MERI, S. (1999). The factor H protein family. Immunopharmacology 42, 53-60.